Please login to the form below

pricing model

This page shows the latest pricing model news and features for those working in and with pharma, biotech and healthcare.

US start-up EQRx promises approach that will slash drug prices

EQRx is co-founded by Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center whose academic interests focus on pricing as well as ... Bach recently proposed a model for selecting drugs for pricing

Latest news

Senate grilling makes pharma CEOs squirm, but give little ground

a cap on Medicare out of pocket payments, and supported value-based payments as a future pricing model. ... grilling. Despite being a longstanding critic of pharma’s pricing, Grassley has also indicated he wants to work with the sector on reform if
Amgen CEO says Aimovig is “one of most successful launches”

The Repatha discount comes as the US administration is ramping up the pressure on the biopharma industry on drug pricing, most recently proposing a reference pricing model to bring process closer
US pricing plan slammed for imposing “foreign price controls”

Gellad also says in a blog post on Stat News that the plans are long on rhetoric but short on concrete plans to implement the reference pricing system, providing “just a
Safety first: AI adoption in the healthcare sector

Cost: agree a clear pricing model, which could be licence- or transaction-based and may also have elements of risk and reward.
Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched

evidence route which would demonstrate the benefits of the treatment and allow an outcomes-based pricing model.

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Assessing the risks in annuity pricing models

The challenge of adapting pricing models to accommodate new therapies. By Walter Colasante. ... pricing model.
Brexit and Trump

that we need to return to servicing a high-volume, low-cost model in consumer healthcare, and a parity pricing model in Rx.
Pharma deals in September 2015

to pursue a “robust” pricing model. ... Pharmaceuticals. He has also written a letter to employees to assuage their concerns over company's business model, potential exposure and the fall in the company's stock price (it fell
Interview: Richard Bergström, EFPIA

These are good examples of where legislation helps promote innovation, but unfortunately it's the access to markets, pricing and reimbursement that are deteriorating. ... I have worked very closely with the Swedish government to shape value-based-pricing.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Innovation in pharma: the highs and lows of the current healthcare economy

concerns. New entrants at both ends of the pricing spectrum. So while challenges remain, biosimilars seem to be finding their place in the market and creating a new and interesting dynamic, ... the system with a manageable pricing model to suit.
Ed Schoonveld - new article

Following the publication of the new edition of The Price of Global Health, Ed Schoonveld writes about the industry's need for new drug pricing model. ... Does the drug industry need a new pricing model? Read Ed Schoonveld's article here . The new
Emerging Markets: The Second Tier

Determine your pricing model: overcome governmental challenges and hear about what worked for Roche in Vietnam. ... Safeguard your reputation:employ a model of good corporate governance and learn how to overcome local corruptio n.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa: Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment: International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?: Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...